CYXO — Cyxone AB Share Price
0.000.00%
Last trade - 00:00- SEK18.74m
- SEK2.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 1.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.09% | ||
| Return on Equity | -53.52% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The Company's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The Company has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.
Directors
- Bert Junno CHM (55)
- Tara Heitner CEO (52)
- Ola Skanung CFO (57)
- Malin Berthold COO (58)
- Mikael Lindstam DRC (55)
- Theresa Comiskey Olsen IND (58)
- Saad Gilani IND (50)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 13th, 2015
- Public Since
- June 7th, 2016
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 215,926,036
- Address
- Adelgatan 21, MALMO, 211 22
- Web
- https://cyxone.com/
- Phone
- Contact
- Carl-Magnus Hoegerkorp
- Auditors
- KPMG AB
Upcoming Events for CYXO
Cyxone AB Annual Shareholders Meeting
Cyxone AB Annual Shareholders Meeting
Q2 2024 Cyxone AB Earnings Release
Similar to CYXO
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the Cyxone AB share price?
As of Today at 19:06 UTC, shares in Cyxone AB are trading at SEK0.09. This share price information is delayed by 15 minutes.
How has the Cyxone AB share price performed this year?
Shares in Cyxone AB last closed at SEK0.09 and the price had moved by -87.86% over the past 365 days. In terms of relative price strength the Cyxone AB share price has underperformed the FTSE Global All Cap Index by -88.6% over the past year.
What are the analyst and broker recommendations for Cyxone AB?
The overall consensus recommendation for Cyxone AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cyxone AB dividend yield?
Cyxone AB does not currently pay a dividend.
Does Cyxone AB pay a dividend?
Cyxone AB does not currently pay a dividend.
When does Cyxone AB next pay dividends?
Cyxone AB does not currently pay a dividend.
How do I buy Cyxone AB shares?
To buy shares in Cyxone AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyxone AB?
As of the previous close price of SEK0.09, shares in Cyxone AB had a market capitalisation of SEK18.74m.
Where are Cyxone AB shares listed?
Here are the trading details for Cyxone AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: CYXO
What kind of share is Cyxone AB?
Based on an overall assessment of its quality, value and momentum Cyxone AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyxone AB share price forecast for 2024?
The analyst consensus target price for shares in Cyxone AB is SEK4.20. That is 4738.71% above the last closing price of SEK0.09.
Analysts covering Cyxone AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.13 for the next financial year.
What is the trend in the Cyxone AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyxone AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -56.66%.
As of the last closing price of SEK0.09, shares in Cyxone AB were trading -60.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyxone AB PE Ratio?
The Cyxone AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyxone AB?
Cyxone AB's management team is headed by:
- Bert Junno - CHM
- Tara Heitner - CEO
- Ola Skanung - CFO
- Malin Berthold - COO
- Mikael Lindstam - DRC
- Theresa Comiskey Olsen - IND
- Saad Gilani - IND